JP2019515884A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515884A5 JP2019515884A5 JP2018549902A JP2018549902A JP2019515884A5 JP 2019515884 A5 JP2019515884 A5 JP 2019515884A5 JP 2018549902 A JP2018549902 A JP 2018549902A JP 2018549902 A JP2018549902 A JP 2018549902A JP 2019515884 A5 JP2019515884 A5 JP 2019515884A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- pharmaceutical composition
- composition according
- day
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 239000003112 inhibitor Substances 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000000977 initiatory effect Effects 0.000 claims 2
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 claims 2
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 claims 1
- 102000003958 Glutamate Carboxypeptidase II Human genes 0.000 claims 1
- 239000002139 L01XE22 - Masitinib Substances 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 1
- JACAAXNEHGBPOQ-LLVKDONJSA-N Talampanel Chemical compound C([C@H](N(N=1)C(C)=O)C)C2=CC=3OCOC=3C=C2C=1C1=CC=C(N)C=C1 JACAAXNEHGBPOQ-LLVKDONJSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims 1
- 229960004755 ceftriaxone Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 229960001848 lamotrigine Drugs 0.000 claims 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims 1
- 229960004655 masitinib Drugs 0.000 claims 1
- 230000002025 microglial effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229960004181 riluzole Drugs 0.000 claims 1
- 230000003381 solubilizing effect Effects 0.000 claims 1
- 229950004608 talampanel Drugs 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021204244A JP2022037132A (ja) | 2016-03-25 | 2021-12-16 | 筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16162490 | 2016-03-25 | ||
| EP16162490.3 | 2016-03-25 | ||
| PCT/EP2017/057134 WO2017162884A1 (en) | 2016-03-25 | 2017-03-24 | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021204244A Division JP2022037132A (ja) | 2016-03-25 | 2021-12-16 | 筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515884A JP2019515884A (ja) | 2019-06-13 |
| JP2019515884A5 true JP2019515884A5 (enExample) | 2020-03-12 |
| JP7250312B2 JP7250312B2 (ja) | 2023-04-03 |
Family
ID=55637258
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018549902A Active JP7250312B2 (ja) | 2016-03-25 | 2017-03-24 | 筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用 |
| JP2021204244A Pending JP2022037132A (ja) | 2016-03-25 | 2021-12-16 | 筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021204244A Pending JP2022037132A (ja) | 2016-03-25 | 2021-12-16 | 筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10092564B2 (enExample) |
| EP (1) | EP3240538B1 (enExample) |
| JP (2) | JP7250312B2 (enExample) |
| KR (1) | KR102293847B1 (enExample) |
| CN (1) | CN108883108B (enExample) |
| AU (1) | AU2017236177B2 (enExample) |
| BR (1) | BR112018069515A2 (enExample) |
| CA (1) | CA3018635C (enExample) |
| DK (1) | DK3240538T3 (enExample) |
| EA (1) | EA038531B1 (enExample) |
| ES (1) | ES2899929T3 (enExample) |
| HU (1) | HUE057398T2 (enExample) |
| IL (1) | IL261856B (enExample) |
| MX (1) | MX390495B (enExample) |
| NZ (1) | NZ745778A (enExample) |
| PL (1) | PL3240538T3 (enExample) |
| PT (1) | PT3240538T (enExample) |
| SG (1) | SG11201808106YA (enExample) |
| SI (1) | SI3240538T1 (enExample) |
| WO (1) | WO2017162884A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| EP2911664B1 (en) | 2012-10-25 | 2019-05-08 | The General Hospital Corporation | Combination therapies for the treatment of alzheimer's disease and related disorders |
| US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
| AU2014340182B2 (en) | 2013-10-22 | 2019-05-23 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| CA3033079A1 (en) * | 2016-08-31 | 2018-03-08 | The General Hospital Corporation | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases |
| KR20200056465A (ko) | 2016-11-25 | 2020-05-22 | 주식회사 지뉴브 | 신경줄기세포의 분화 촉진 및 보호용 조성물 및 이를 이용하여 신경재생을 유도하는 방법 |
| EP4324523A3 (en) * | 2017-03-28 | 2024-05-01 | Novartis AG | New methods for the treatment of multiple sclerosis |
| MY205552A (en) * | 2017-05-30 | 2024-10-25 | Deciphera Pharmaceuticals Inc | Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl ]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alpha |
| KR102874471B1 (ko) | 2018-03-05 | 2025-10-31 | 매사추세츠 아이 앤드 이어 인퍼머리 | 콜로니 자극 인자의 표적화에 의한 녹내장 및 시신경병증 치료법 |
| CA3105392A1 (en) | 2018-07-02 | 2020-01-09 | The General Hospital Corporation | Powdered formulations of cromolyn sodium and .alpha.-lactose |
| EP3893945A4 (en) | 2018-12-10 | 2022-11-30 | The General Hospital Corporation | CROMOGLYC ESTERS AND THEIR USES |
| CN112618717A (zh) * | 2019-09-24 | 2021-04-09 | 北京大学深圳研究生院 | Btk抑制剂用于治疗肌萎缩侧索硬化症的用途 |
| AU2020417282B2 (en) * | 2019-12-30 | 2023-08-31 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| US12458622B2 (en) | 2020-04-06 | 2025-11-04 | The General Hospital Corporation | Methods of treatment of coronavirus-induced inflammation conditions |
| WO2025113494A1 (zh) * | 2023-11-27 | 2025-06-05 | 浙江径科医药有限公司 | 多环类化合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW225528B (enExample) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| US8450302B2 (en) | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| MXPA05001277A (es) | 2002-08-02 | 2005-10-06 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit. |
| AU2008214679A1 (en) | 2007-02-13 | 2008-08-21 | Ab Science | Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors |
| US8906357B2 (en) | 2010-04-20 | 2014-12-09 | Ab Science | Treatment of multiple sclerosis with masitinib |
| WO2013010015A2 (en) | 2011-07-13 | 2013-01-17 | Cytokinetics, Inc. | Combination als therapy |
| MX369999B (es) * | 2012-10-04 | 2019-11-28 | Ab Science | Uso de masitinib en combinación con gemcitabina para el tratamiento de cáncer pancreatico en subpoblaciones de pacientes identificados en base al factor predictor de la intensidad de dolor. |
| EP3670515B1 (en) * | 2013-03-15 | 2024-03-06 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone compounds and methods of treating disorders |
| US20160263110A1 (en) * | 2013-11-04 | 2016-09-15 | Ab Science | Use of masitinib for treatment of amyotrophic lateral sclerosis |
-
2017
- 2017-03-24 SG SG11201808106YA patent/SG11201808106YA/en unknown
- 2017-03-24 SI SI201730997T patent/SI3240538T1/sl unknown
- 2017-03-24 AU AU2017236177A patent/AU2017236177B2/en active Active
- 2017-03-24 CA CA3018635A patent/CA3018635C/en active Active
- 2017-03-24 EP EP17712175.3A patent/EP3240538B1/en active Active
- 2017-03-24 CN CN201780019760.9A patent/CN108883108B/zh active Active
- 2017-03-24 DK DK17712175.3T patent/DK3240538T3/da active
- 2017-03-24 WO PCT/EP2017/057134 patent/WO2017162884A1/en not_active Ceased
- 2017-03-24 US US15/545,800 patent/US10092564B2/en active Active
- 2017-03-24 ES ES17712175T patent/ES2899929T3/es active Active
- 2017-03-24 HU HUE17712175A patent/HUE057398T2/hu unknown
- 2017-03-24 PL PL17712175T patent/PL3240538T3/pl unknown
- 2017-03-24 KR KR1020187026871A patent/KR102293847B1/ko active Active
- 2017-03-24 PT PT177121753T patent/PT3240538T/pt unknown
- 2017-03-24 JP JP2018549902A patent/JP7250312B2/ja active Active
- 2017-03-24 NZ NZ745778A patent/NZ745778A/en not_active IP Right Cessation
- 2017-03-24 BR BR112018069515A patent/BR112018069515A2/pt not_active Application Discontinuation
- 2017-03-24 MX MX2018011349A patent/MX390495B/es unknown
- 2017-03-24 EA EA201800499A patent/EA038531B1/ru unknown
-
2018
- 2018-09-20 IL IL261856A patent/IL261856B/en unknown
-
2021
- 2021-12-16 JP JP2021204244A patent/JP2022037132A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515884A5 (enExample) | ||
| KR101178318B1 (ko) | 효과적인 의약의 사용법 및 부작용 발현의 방어에 관한방법 | |
| JP2023002662A5 (enExample) | ||
| JP5911929B2 (ja) | 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬 | |
| AU2018371177A1 (en) | Dosage regimen of vidofludimus for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases | |
| SE9901573D0 (sv) | New compounds | |
| JP2019520344A5 (enExample) | ||
| RU2333209C9 (ru) | Композиции и способы для борьбы с дисфункциями нижних мочевых путей с использованием агонистов дельта-опиоидных рецепторов | |
| JPWO2023054732A5 (enExample) | ||
| JP2018517759A5 (enExample) | ||
| JP2019531286A5 (enExample) | ||
| WO2004081012A1 (ja) | 抗腫瘍効果増強剤及び抗腫瘍剤 | |
| MXPA04012604A (es) | áCIDO 3-MERCAPTOPENTANOICO 2,5 DISUSTITUIDO. | |
| HU222888B1 (hu) | Anilid vegyületek alkalmazása I típusú allergiás betegségek megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállítására | |
| SE9901572D0 (sv) | New compounds | |
| JPWO2023078333A5 (enExample) | ||
| WO2020067333A1 (ja) | 線維症治療用医薬組成物 | |
| CN113557016A (zh) | 衣壳组装调节剂固体配制品 | |
| HUP0203790A2 (hu) | (6-Metoxi-2-naftil)-ecetsav prodrugokat tartalmazó gyógyszerkészítmények alkalmazása gyulladás kezelésére | |
| WO2019004465A1 (ja) | ペマフィブラートを含有する医薬 | |
| JPWO2019234240A5 (enExample) | ||
| CA2240278A1 (en) | Malignant tumor metastasis inhibitors | |
| JPWO2020037152A5 (enExample) | ||
| JP2023518430A (ja) | 感染症の治療におけるブシラミンの使用 | |
| WO2021066136A1 (ja) | 筋ジストロフィー治療薬 |